Ctla 4 pe cy7

Manufactured by BioLegend

CTLA-4 PE/Cy7 is a fluorescent-conjugated antibody that binds to the CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) molecule, which is expressed on the surface of activated T cells. This antibody can be used for the detection and analysis of CTLA-4 expression on cells by flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

CTLA-4 (26 citations) CTLA-4-PE (8 citations) PE-conjugated anti-CTLA-4 (UC10-4F10-11); PE-Cy7–conjugated anti-CD25 (PC81); biotin-conjugated anti-CD8b (53-5.8), (2 citations)

3 protocols using ctla 4 pe cy7

Comprehensive Treg Phenotyping by Flow Cytometry

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies used for flow cytometry were as follows: CD4-Pacific Blue, CD25-PE, CD25-APC, CD127-FITC, Foxp3-PE, CD38-PE-Cy7, AnnexinV-PE, PD1-APC, CD8-FITC, CTLA4-PE-Cy7, CD44-FITC, CD62L-FITC, ICOS-FITC, GITR-PE, OX40-FITC, CD138-FITC, PD-L1-PE, and their isotype-matched mAbs (all from Biolegend). Intracellular staining of Foxp3, CTLA4, GITR, and OX40 were performed after fixation and permeabilization using cytofix/cytoperm kit (BD Biosciences), according to manufacturer’s protocol. Tregs were gated as CD4+CD25highFoxp3+ cells in CD4+ population and then sequential markers were assayed on Tregs, whereas CD4+CD25− cells were identified as Tcons. The remaining CD4+CD25low/intermediate subset was excluded in the current study because of their limited immunosuppressive activity compared with CD25high population (34 (link)). To avoid the effect of permeabilization when apoptosis assay was performed, CD4+CD25highCD127low/− cells were identified as Tregs (35 (link)). All flow cytometry was performed by BD FACS CantoII, and analyzed on FlowJo software version 10 (Treestar).

Feng X., Zhang L., Acharya C., An G., Wen K., Qiu L., Munshi N., Tai Y.T, & Anderson K.C. (2017). Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(15), 4290-4300.

+ Open protocol

+ Expand

Multiparametric Flow Cytometry of Murine Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood was taken routinely from anesthetized mice (retrobulbar venous plexus). Spleen and tumor tissues were dissociated. Single cells were stained with a panel of conjugated monoclonal antibodies (mAb, 0.125 μg to 1.5 μg each). Zombie NIR™ Fixable Viability Kit by Biolegend (San Diego, United States) staining was performed following the protocol Zombie NIR™ Fixable Viability Kit by Biolegend, extracellular staining was performed following the protocol BD Horizon Briliant Stain Buffer (BD Bioscience), followed by lysis and intracellular staining using the protocol of True-Nuclear™ Transcription Factor Buffer Set by Biolegend. Measurements were performed on a spectral flow cytometer (Cytek™ Aurora). For extracellular stainings Gr1 Alexa Fluor700, CD8 FITC, CD4 APC Fire, CD11b BV570, PD-L1 BV421, NK1.1 BV605, CD19 Spark Blue (Biolegend), CD25 PerCP-eFluor710 (Thermofisher), CD83 BV750, PD-1 BV650 (BD Bioscience) and for intracellular stainings CTLA-4 PE/Cy7, CD3 PerCP, and Foxp3 Alexa Fluor 647 (Biolegend) were used. Data were analyzed using SpectroFlow™ Version 2.2.0.3. and FlowJo™ Version 10.6.1.

Salewski I., Henne J., Engster L., Krone P., Schneider B., Redwanz C., Lemcke H., Henze L., Junghanss C, & Maletzki C. (2022). CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors. Oncoimmunology, 11(1), 2094583.

+ Open protocol

+ Expand

Multiparameter Immune Profiling of PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following anti-human monoclonal antibodies (mAb) were used for staining: CD3-Alexa Fluor 405 (#CD0326, Invitrogen), CD4-AF700 (#560836, BD Biosciences), PD-1-APC (#17–9969-41, eBioscience), CTLA-4 PE/Cy7 (#349914, Biolegend), and their respective isotype controls. PE-conjugated EGFR:853–861 tetramer and MAGE:271–279 tetramer were synthesized by the NIH Tetramer Facility (Emory University), and the HPV E7:11–20 Pentamer was commercially obtained (#095, ProImmune). Antibodies and tetramers were pre-titrated using activated as well as non-activated PBMC to determine optimal staining dilutions.

Kansy B.A., Shayan G., Jie H.B., Gibson S.P., Lei Y.L., Brandau S., Lang S., Schmitt N.C., Ding F., Lin Y, & Ferris R.L. (2018). T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. Oncoimmunology, 7(11), e1494112.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!